Progress reported with candidate dengue vaccine

July 25, 2012

Trials in Thailand with a candidate vaccine for dengue, a potentially fatal mosquito-borne disease, have shown it to protect against three of the four virus strains, its French maker said Wednesday.

The first trials in humans proved the vaccine was safe and represented a key milestone in the quest for a dengue jab, vaccine-maker Sanofi Pasteur executive vice president Michel De Wilde said in a statement.

"This is also an important development for global public health, since there is currently no specific treatment or prevention for dengue."

The says the disease infects between 50 million and 100 million people every year and kills more than 20,000 -- mainly in tropical and of Asia and , but expanding rapidly including to parts of Europe.

Researchers estimate that some three billion people live in regions susceptible to dengue contagion and another 20 million tourists pass through them.

The disease caused by one of four virus serotypes results in fever, aches, rashes, vomiting and in rare cases death. Children are especially vulnerable.

Sanofi Pasteur said its was effective against three of the four virus serotypes and analyses were under way "to understand the lack of protection for the fourth".

The company conducted trials on 4,000 children aged four to 11 in Thailand's Muang district, the results of which have yet to be published in a peer-reviewed medical journal.

Larger Phase III trials with 31,000 adults and children are taking place in 10 countries in Asia and Latin America.

Explore further: Human antibody for dengue virus isolated

Related Stories

Human antibody for dengue virus isolated

June 22, 2012
(Phys.org) -- A group of scientists in Singapore and the UK have isolated a human antibody capable of effectively neutralizing the mosquito-borne dengue virus. Dengue fever is currently incurable and infects an estimated ...

Recommended for you

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

Researchers identify information gaps about opioid antidote naloxone

November 27, 2017
The nation's opioid epidemic kills 91 people a day, according to the U.S. Centers for Disease Control and Prevention. The death toll would be even higher, were it not for emergency responders' heavy reliance on naloxone as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.